Drug Profile
SX 013
Latest Information Update: 22 Jan 2002
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 22 Jan 2002 Discontinued-I for Obesity in United Kingdom (Unknown route)
- 21 Sep 2000 First human study completed with formulation called SX 013
- 04 Jul 2000 Phase-I clinical trials for Obesity in United Kingdom (Unknown route)